Treating and Preventing Adolescent Mental Health Disorders: Treating and Preventing Adolescent Mental Health Disorders

Home > Table of Contents

Book Title: Treating and Preventing Adolescent Mental Health Disorders > pp. [799]

UNDEFINED: AUTHORS

Treating and Preventing Adolescent Mental Health Disorders

Print ISBN 9780195173642, 2005
pp. [799]

alcohol abuse and dependence , 359–60

anorexia nervosa , 259–61 , 260 t, 262–63

bulimia nervosa , 261–63 , 262 t

eating disorders , 259–63 , 260 t, 262 t

schizophrenia , 78

substance use disorders , 336 , 374 , 374 f

Dialectical behavioral therapy

for suicidal adults , 477–78

for suicidal youth , 480 t, 482

Diathesis-stress model of depression , 11–12

Dietary restraint, definition , 304

Dieting . See also Weight loss

anorexia nervosa and , 308–9

bulimia nervosa and , 314

definition , 304

eating disorders and , 304 , 317–18

professionally administered

effects on eating behavior , 317–18

effects on psychological status , 318

research with adults , 318–19

youth-based program , 316 , 317

Disorder, harmful dysfunction account of , 163–64

Disorganization, in schizophrenia , 82

Disruptive behavior disorders, plus depression , 9 , 37–38

Disulfiram, for alcohol use disorders , 405–6

Divaloproex

for bipolar disorder

in adolescents , 52 , 52 t

in adults , 50

maintenance therapy , 54

with lithium, for bipolar disorder , 53

Dopamine

in alcohol use , 387

cortisol and , 97

in drug addiction , 375–76 , 381–82 , 388

in schizophrenia , 99

in smoking , 386

Dorsal lateral prefrontal cortex, developmental changes , xxix

Dot Probe Attention Allocation Task , 173–74

Double depression , 6

Drug abuse . See Substance use disorders

Drug Abuse Resistance Education (DARE), 418

Drug Abuse Warning Network (DAWN), 343

Drug courts, juvenile , 577

Drug dealing, school professional findings , 601–2 , 602 t

Drug screening . See Substance use disorders, identification

DSM-IV diagnostic criteria . See Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria

Duloxetine, for major depressive disorder , 42

Dysbindin, as schizophrenia susceptibility gene , 104

Dysthymic disorder

plus major depressive disorder , 6

versus major depressive disorder , 7 , 7 t

secondary , 6

Eating disorders , xxvii . See also Anorexia nervosa; Bulimia nervosa

combination therapy , 294

community attitudes toward , 533 , 534 t

comorbidity , 272–73 , 327

diagnostic criteria , 259–63 , 260 t, 262 t, 326

diagnostic migration , 274 , 327

dieting and , 304 , 317–18

epidemiology , 263–72 , 275 t, 277 t, 326–27

ethnic differences , 271

etiology , 258–59

medical complications , 275–81 , 276 t, 327

not otherwise specified , 258 , 262 , 291

obesity as risk factor for , 315–19 , 331–32

outcome , 273–74 , 327

pharmacotherapy , 291–94 , 297–98 , 328–29

prevalence , 263–72 , 275 t, 277 t

prevention programs , 319–23

combined , 322

in high-risk populations and settings , 322

research agenda , 332

targeted , 321–22

universal , 319–21

primary care physician findings , 583–84 , 584 t, 586 , 586t–588 t, 587 , 591 t

psychosocial therapy , 284–91 , 294–97 , 327– 28

relapse prevention , 294–98 , 329

research agenda , 326–32

risk factors , 304–19 , 306 t, 330–32

school professional findings , 601 , 602 t

symptoms , 270–71

treatment , 284–301

guidelines , 300–301

issues specific to adolescents , 299–300

research agenda , 327–30

weight restoration , 280–81

Ecological approach to youth development , 501

“Ecstasy” (MDMA) use

anxiety and , 229

clinical aspects , 367–68

evolution , 341

liquid , 369–70

Education . See Psychoeducation; Training

Effectiveness, organizational requirements for , 559

Electroencephalography

in anxiety disorders , 179

in schizophrenia , 88–89

Electrolyte abnormalities, in eating disorders , 276 t

Electrophysiology, in schizophrenia , 88–95

end p.799